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Abstract
This study investigated the effects of the presence of type 2 diabetes mellitus (T2D) and/or chronic liver disease (CLD) on the
incidence and prognosis of dementia during a 10-year period in Korea using a nationwide population-based dataset from the Korea
National Health Insurance Service.
To assess the impact of T2D and CLD on the incidence of dementia, we included subjects aged≥60 years without dementia, T2D,
and CLD from 2003 to 2005. We created another cohort for evaluating the all-cause mortality in subjects with dementia between
2003 and 2005. The participants were categorized into 4 groups: control (neither CLD nor T2D), CLD-only, T2D-only, and T2D-and-
CLD groups, and they were followed up until 2013.
The incidence of dementia was higher in the T2D-only group than in the control and CLD-only groups (2.78 vs. 2.04 and 2.00 per
1000 person-years). After adjustment for age, gender, and comorbid conditions, both T2D and CLD increased the risk of any type of
dementia; however, the impact of CLD alone was much lower [hazard ratio (HR) 1.07, 95% conﬁdence interval (CI): 1.06–1.08] than
that of T2D alone (HR 1.27, 95% CI: 1.27–1.28). The risk of dementia did not signiﬁcantly change in patients with the co-occurrence
of T2D and CLD compared to those with T2D alone. The all-cause mortality rate was the lowest in the control group (2.59 per 1000
person-years) and the highest in the T2D-and-CLD group (3.77 per 1000 person-years). Presence of T2D or CLD alone was
associated with higher mortality (HR 1.46 and HR 1.21, respectively) compared with in the absence of both the diseases.
Furthermore, the presence of both the diseases further signiﬁcantly increased the mortality rate compared to the presence of each
disease alone (HR 1.67, 95% CI: 1.65–1.69).
In conclusion, this study found that the incidence of dementia was much higher in patients with T2D. CLD was associated with a
modest increase in risk of dementia; however, there was no additive effect with T2D. In the population with dementia, however, the
presence of CLD was associated with high mortality in patients with or without T2D.
Abbreviations: CKD = chronic kidney disease, CLD = chronic liver disease, COPD = chronic obstructive pulmonary disease, HR
= hazard ratio, ICD = International Classiﬁcation of Diseases, NAFLD = nonalcoholic fatty liver disease, NHIS = National Health
Insurance Service, OR = odds ratio, PAOD = peripheral arterial occlusive disease, SD = standard deviation, T2D = type 2 diabetes
mellitus.
Keywords: dementia, diabetes mellitus, liver diseases, type 2
1. Introduction populations, the proportion of which is projected to be moreWith the progression of population aging, dementia is becoming
one of the most rapidly increasing diseases in the world.[1] Korea
is one of the countries with the fastest growing elderlyEditor: Durga Tripathi.
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1than one third of whole population by 2050.[2] Accordingly, the
number of patients with dementia in Korea is expected to increase
rapidly.[3] Dementia refers to a group of symptoms that include
severe memory loss and problems with thinking, solving
problems, and using language. Dementia can be generally
classiﬁed as Alzheimer disease or vascular dementia.[4] Further-
more, since all forms of dementia result on deteriorated quality of
life and is related to mortality, it is considered as a serious health
care issue.[3]
With the increase in the elderly population, the prevalence of
various chronic diseases including type 2 diabetes mellitus
(T2D)[5] and chronic liver disease (CLD)[6] are also rising. CLD
consists of various liver diseases with recurring damage and
recovery of hepatic parenchyma, resulting in ﬁbrosis of liver and
eventually leading to liver cancer.[7] Causes of CLD include
toxins, viral infections, alcohol, and nonalcoholic fatty liver that
increase with obesity.[7]
Many studies have investigated the relationship between
diabetes mellitus and dementia.[8,9] T2D has been shown to
increase the risk of Alzheimer or vascular dementia by up to
60%.[10] Another study showed poor prognosis for dementia in
patients who also suffered from T2D.[11] Even though the studies
Kim et al. Medicine (2017) 96:47 Medicinewere inconclusive, type 1 diabetes is also considered to increase
the risk of dementia.[12] However, to date, there is a lack of data
on the correlation between CLD and incidence or prognosis of
dementia; likewise, the simultaneous inﬂuence of diabetes and
CLD on the incidence or prognosis of dementia remains largely
unexplored.
Therefore, in this study, we investigated the effects of the
presence of T2D and CLD on the incidence rate of dementia
during a 10-year period in Korea using a nationwide population-
based dataset. Furthermore, we also studied the impacts of T2D
and CLD on the all-cause mortality in patients with dementia.2. Methods
2.1. Database used in the study
We used the national health information database maintained by
National Health Insurance Service (NHIS). NHIS is the national
healthcare program of Korea which covers the entire Korean
population as a social insurance beneﬁts scheme. The database
contains eligibility and demographic information regarding
health insurance as well as data on medical aid beneﬁciaries,
medical bill details, medical treatment, disease histories, and
prescriptions.[13] We analyzed the information for each individ-
ual with an unidentiﬁable code including age, sex, diagnosis, and
prescribed drugs. The personal privacy of each participant was
protected by deidentiﬁcation of the national insurance claims
data for analysis. The present study was approved by the NHIS
inquiry commission and the institutional review board of the
Korean National Institute for Bioethics Policy (P01-201504-21-
005). Informed consent was exempted by the board. To validate
the database and screen for information accuracy, the expert
committee from the Korean Diabetes Association reviewed
the database regularly during this analysis. The committee
decided the suitability of the dataset and evaluated results of the
analysis.2.2. Study design
2.2.1. Cohort to determine the incidence of dementia. To
evaluate the impact of T2D and CLD on the incidence of
dementia, we included subjects aged≥60 years without dementia,
T2D, and CLD from 2003 to 2005. We categorized the subjects
into 4 groups according to the absence or presence of T2D and/or
CLD, namely, the neither-CLD-nor-T2D (control), CLD-only,
T2D-only, and T2D-and-CLD groups. Subjects were identiﬁed
using the International Classiﬁcation of Diseases (ICD)-10 codes
as outlined by the 10th revision of International Statistical
Classiﬁcation of Diseases. T2D was deﬁned if antidiabetic drugs
were prescribed at least 2 times and the ICD-10 codes with E11,
E12, E13, or E14 was assigned at least 2 times per patient. CLD
was deﬁned as ICD-10 codes with B18, K70, K71.3-71.5, K71.7,
K72.1, K72.7, K72.9, K73, K74, or K76 at least 2 times. This
cohort was followed up until the end of the study period (i.e.,
December 31, 2013), or until the date of diagnosis with any type
of dementia. The follow-up time in person-years was calculated
for each study subject until the occurrence of dementia. Dementia
was deﬁned if antidementia drugs were prescribed at least 2 times
and the codes with Alzheimer disease (ICD-10 F00 or G30),
vascular dementia (ICD-10 F01.0, F01.1, F01.2, F01.3, F01.8, or
F01.9), or other dementia (ICD-10 F02, F03, G23.1, G31.0,
G31.1, G31.82, G31.83, G31.88, or F10.7) were assigned;
antidementia drugs, belonging to the 4 classes, included
rivastigmine, galantamine, memantine, and donepezil hydro-2chloride. The detailed diagnosis of dementia was deﬁned as the
ﬁrst prescription of antidementia drugs since diagnosis. When
there were both Alzheimer disease and vascular dementia (2
codes each), the ﬁnal diagnosis was deﬁned as vascular dementia.
If there was neither Alzheimer disease nor vascular dementia, the
diagnosis was deﬁned as other dementia. Other considered
comorbidities at the baseline were hypertension (ICD-10 I10, I11,
I12, I13, or I15), dyslipidemia (ICD-10 E78), ischemic heart
disease (ICD-10 I20, I21, I22, I23, I24, or I25), cardiac
arrhythmia (ICD-10 I44, I45, I46, I47, or I49), heart failure
(ICD-10 I50, I110, I130, or I132), peripheral arterial occlusive
disease (PAOD) (ICD-10 I70 or I73.9), asthma/chronic obstruc-
tive pulmonary disease (COPD) (ICD-10 J40, J41, J42, J43, J44,
J45, or J47), chronic kidney disease (CKD) (ICD-10 N18 or
N19), and depression (ICD-10 F32 or F33).
2.2.2. Cohort for all-cause mortality.We made another cohort
for evaluation all-cause mortality in dementia population. We
selected subjects aged ≥60 years recorded to have any type of
dementia between 2003 and 2005, and categorized them into 4
groups: neither-CLD-nor-T2D (control), CLD-only, T2D-only,
and T2D-and-CLD groups. The deﬁnitions of dementia, T2D,
and CLD were identical to those in the previous cohort.
Information on mortality until 2013 was available for all
subjects in this cohort. The cohort was followed up until the end
of the study period (December 2013), or until the date of death
for patients who died.
2.3. Statistical analysis
Continuous variables were presented as means ± standard
deviation and categorical variables were presented as numbers
and percentages. To compare characteristics between cohorts,
analysis of variance was used for continuous variables and the
chi-square test was used for binary and categorical variables.
The incidence rates of dementia were calculated by dividing the
number of incident cases by the total follow-up period. The
incidence rates of dementia and all-cause mortality rates were
presented as 1000 person-years. Multivariate Cox regression
modelswere used to evaluate the association between the absence
or presence of T2D and/or CLD and the incidence of new-onset
dementia and all-cause mortality rate. Model 1 examined the
unadjusted hazard ratios (HRs). Model 2 provided the age- and
sex-adjusted HR for the incidence of dementia and mortality
rate. Model 3 was adjusted for age, sex, classes of national
health insurance system, place of residence, and other comor-
bidities, including hypertension, dyslipidemia, ischemic heart
disease, cerebrovascular disease, heart failure, PAOD, COPD,
CKD, and depression. The cumulative all-cause mortality
according to the presence of T2D and/or CLD was calculated
by using the Kaplan-Meier curves; the log-rank test was
performed to analyze differences among the groups. The
signiﬁcance level was set at 2-sided P< .05. All statistical
analyses were performed using SPSS version 22 and SAS version
9.4 (SAS Institute, Cary, NC).3. Results
3.1. Baseline characteristics of the study population
In our nationwide dataset, we identiﬁed 388,636 people who
were newly diagnosed with CLD and without T2D (designated as
the CLD-only group) from 2003 to 2005. Furthermore, there
were 749,161 people with newly diagnosed T2D, without CLD
Table 1
Baseline characteristics of the participants according to the presence of type 2 diabetes mellitus and/or chronic liver disease.
Neither T2D nor CLD (control) CLD-only T2D-only T2D-and-CLD
(n=5,080,631) (n=388,636) (n=749,161) (n=122,590) P
Age 69.6±7.4 68±6.2 69.3±6.4 67.9±5.8 <.001
Sex (male) 2,107,780 (41.5) 192,654 (49.6) 308,508 (41.2) 62,823 (51.3) <.001
Comorbidities
Hypertension 1,719,280 (33.84) 186,530 (48) 485,842 (64.85) 79,617 (64.95) <.001
Dyslipidemia 420,797 (8.28) 88,887 (22.87) 193,907 (25.88) 41,344 (33.73) <.001
Ischemic heart disease 342,445 (6.74) 49,667 (12.78) 119,692 (15.98) 21,768 (17.76) <.001
Cerebrovascular 301,147 (5.93) 33,952 (8.74) 92,590 (12.36) 14,585 (11.9) <.001
Disease
Heart failure 96,828 (1.91) 13,490 (3.47) 25,525 (3.41) 5040 (4.11) <.001
PAOD 57,542 (1.13) 11,505 (2.96) 24,517 (3.27) 6163 (5.03) <.001
COPD 769,556 (15.15) 95,752 (24.64) 139,561 (18.63) 28,654 (23.37) <.001
Chronic kidney disease 20,067 (0.39) 4693 (1.21) 13,991 (1.87) 3075 (2.51) <.001
Depression 159,300 (3.14) 23,729 (6.11) 38,887 (5.19) 8227 (6.71) <.001
Incidence of dementia
Any dementia 703,369 (13.84) 52,977 (13.63) 139,845 (18.67) 20,534 (16.75) <.001
Alzheimer disease 514,001 (10.12) 38,347 (9.87) 98,773 (13.18) 14,349 (11.7) <.001
Vascular dementia 79,588 (1.57) 6099 (1.57) 18376 (2.45) 2806 (2.29) <.001
Other dementias 109,780 (2.16) 8531 (2.2) 22,696 (3.03) 3379 (2.76) <.001
Values are presented as mean± standard deviation or number (%).
CLD = chronic liver disease, COPD = chronic obstructive pulmonary disease, PAOD = peripheral arterial occlusive disease, T2D = type 2 diabetes mellitus.
Kim et al. Medicine (2017) 96:47 www.md-journal.com(T2D-only group), and 122,590 people with both the diseases
(CLD and T2D group). About 5 million were free of both CLD
and T2D (categorized as the neither-T2D-nor-CLD or control
group).
Baseline characteristics for all groups are shown in Table 1.
The subjects with CLD-only and those with both T2D and CLD
were slightly younger than the people without CLD. In addition,
the comorbidities such as hypertension, dyslipidemia, ischemic
heart disease, cerebrovascular disease, heart failure, and CKDTable 2
The inﬂuence of type 2 diabetes mellitus and/or chronic liver diseas
Incidence per 1000 person-years M
Any dementia
Neither T2D nor CLD 2.04
CLD-only 2.00 0
T2D-only 2.78 1
T2D and CLD 2.48 1
Alzheimer disease
Neither T2D nor CLD 1.49
CLD-only 1.45 0
T2D-only 1.96 1
T2D and CLD 1.73 1
Vascular dementia
Neither T2D nor CLD 0.23
CLD-only 0.23 1
T2D-only 0.37
T2D and CLD 0.34 1
Other dementias
Neither T2D nor CLD 0.32
CLD-only 0.32 1
T2D-only 0.45 1
T2D and CLD 0.41 1.
Model 1 is not adjusted.
Model 2 is adjusted for age and sex.
Model 3 is adjusted for age, sex, classes of national health insurance system, place of residence, hyperten
arterial disease, chronic obstructive pulmonary disease, chronic kidney disease, and depression.
CI = conﬁdence interval, CLD = chronic liver disease, T2D = type 2 diabetes mellitus.
3were much more prevalent in the T2D-only and T2D-and-CLD
groups than in the control or CLD-only groups.3.2. Incidence of dementia according to the presence
of type 2 diabetes or chronic liver disease
The incidence of dementia was higher in the T2D-only group than
in the neither-T2D-nor-CLD group (2.78 vs 2.04 per 1000
person-years) (Table 2). The incidence of any type of dementiae on the incidence of dementia.
Hazard ratio (95% CI)
odel 1 Model 2 Model 3
1 1 1
.98 (0.97–0.99) 1.14 (1.13–1.15) 1.07 (1.06–1.08)
.28 (1.27–1.29) 1.37 (1.36–1.38) 1.27 (1.27–1.28)
.17 (1.15–1.18) 1.40 (1.38–1.42) 1.28 (1.26–1.30)
1 1 1
.97 (0.96–0.98) 1.14 (1.13–1.15) 1.08 (1.07–1.09)
.23 (1.22–1.24) 1.32 (1.31–1.33) 1.25 (1.24–1.26)
.11 (1.09–1.13) 1.35 ((1.33–1.37) 1.25 (1.23–1.27)
1 1 1
.00 (0.97–1.02) 1.10 (1.07–1.12) 1.00 (0.98–1.02)
1.50 (1.47–1.52) 1.557 (1.53–1.58) 1.34 (1.32–1.36)
.41 (1.36–1.47) 1.58 (1.52–1.64) 1.33 (1.28–1.39)
1 1 1
.01 (0.99–1.04) 1.19 (1.16–1.22) 1.11 (1.09–1.14)
.36 (1.34–1.38) 1.45 (1.43–1.47) 1.34 (1.32–1.36)
245 (1.20–1.29) 1.50 (1.45–1.56) 1.35 (1.31–1.40)
sion, dyslipidemia, ischemic heart disease, cerebrovascular disease, heart failure, peripheral occlusive
Kim et al. Medicine (2017) 96:47 Medicinewas lower in the CLD-only group (2.00 per 1000 person-years)
compared to the former 2 groups. This could be due to the fact
that subjects in the CLD-only group were signiﬁcantly younger
than the neither-T2D-nor-CLD group (Table 1). Therefore, we
further used several statistical models to adjust for important
clinical and demographic factors, including, age, gender, the
classes of national health insurance system, place of residence,
and the comorbid medical conditions such as hypertension,
dyslipidemia, ischemic heart disease, stroke, heart failure, PAOD,
COPD, CKD, and depression. After adjustment, T2D markedly
increased the risk of any type of dementia [odds ratios (ORs)
ranging from 1.25–1.34, with all p values< .05) (Table 2).
Presence of CLD alone also signiﬁcantly increased the incidence
of any types of dementia, Alzheimer’s disease and other types of
dementia (ORs ranging from 1.07–1.11, with all p values< .05).
However, the incidence of vascular dementia was not different
between the CLD-only group and the neither-T2D-nor-CLD-
group (OR 1.00, 95% CI: 0.98–1.02). Furthermore, the risk of
dementia did not signiﬁcantly change in patients with the co-
occurrence of T2D and CLD compared to those with T2D alone
(OR 1.27, 95% CI: 1.27–1.28 vs. OR 1.28, 95% CI: 1.26–1.30).3.3. All-cause mortality in patients with dementia based
on underlying comorbidities
Next, to investigate the inﬂuence of T2D or CLD on the
prognosis in patients with dementia, we analyzed the second
cohort. During the follow-up period, a total 1,486,818 patients
died. The incidence of all-cause mortality was the lowest in the
neither-T2D-nor-CLD group (2.59 per 1000 person-years), and
the highest in the T2D-and-CLD group (3.77 per 1000 person-
years) (Table 3). After adjustment for age, sex, and multiple
medical conditions, the presence of T2D or CLD was found to be
associated with higher mortality (OR 1.46, 95% CI: 1.45–1.47,
and OR 1.21, 95%CI: 1.20–1.22, respectively), and the presence
of both diseases signiﬁcantly increased the mortality rate
compared to the neither-T2D-nor-CLD group (OR 1.67, 95%
CI: 1.65–1.69) (Table 3; Fig. 1A). Because the impact of CLD
could be different according to the speciﬁc causes of liver disease,
we categorized CLD into 2 types based on the causative factors:
alcoholic CLD and nonalcoholic CLD. Alcoholic CLD was
deﬁned as ICD-10 codes with K70, and the others were
considered as nonalcoholic CLD. As expected, the mortality
rate was much higher in the patients with both T2D and alcoholic
CLD compared to all other groups during the 7 years of follow-
up (Fig. 1B). Furthermore, there was no difference in the
mortality rates between the nonalcoholic CLD-only and neither-
CLD-nor-T2D groups (Fig. 1B).Table 3
The inﬂuence of type 2 diabetes mellitus and/or chronic liver diseas
Mortality per 1000 person-year M
Neither T2D nor CLD 2.59
CLD-only 2.77 1
T2D-only 3.58 1
T2D and CLD 3.77 1
Model 1 is not adjusted.
Model 2 is adjusted for age and sex.
Model 3 is adjusted for age, sex, classes of national health insurance system, place of residence, hyperten
arterial disease, chronic obstructive pulmonary disease, chronic kidney disease, and depression.
CI = conﬁdence interval, CLD = chronic liver disease, T2D = type 2 diabetes mellitus.
44. Discussion
In the current nationwide population-based, retrospective cohort
study, CLD and T2D increased the incidence of dementia;
however, the co-occurrence of the 2 did not have an additive
effect compared to each disease alone. Among patients with
dementia, CLD increased the all-cause mortality regardless of the
occurrence of T2D. However, the impact of T2D on the all-cause
mortality was much higher than that of CLD.
There have been many studies investigating the relationship
between diabetes mellitus and dementia, recently. T2D, in
particular, has consistently been shown to be associated with
increased risk for mild cognitive impairment,[14] vascular
dementia, and Alzheimer disease.[15,16] Recent meta-analysis
shows that individuals with T2D are at about 60% greater risk
for the development of dementia compared with those without
T2D.[10] Although there are several reports on the association
between type 1 diabetes and cognitive dysfunction,[9,17] this
association is yet to be robustly assessed by the larger population
studies. A retrospective nationwide cohort study from England
showed that type 1 diabetes mellitus was associated with an
elevated risk of any type dementia, Alzheimer disease, and
vascular dementia.[12] Also, an association between diabetic
microvascular complication, such as diabetic retinopathy, and
cognitive impairment has been reported.[18,19] While the exact
mechanisms underlying the association between diabetes mellitus
or its complication and dementia are unclear, numerous
mechanisms have been suggested for this association: brain
vascular lesions,[20] insulin resistance,[21] advanced glycation end
products,[22] and systemic inﬂammation.[23] In addition, several
demographic and socioeconomic factors such as aging, educa-
tion, other comorbidities such as depression, and genetic factors
could also be involved.[24] This present study, however, only
includes T2D, and the relative risk was approximately 1.25 to
1.34 for any dementia or each type of dementia tested. This rate
was comparable with those previously reported in Korea.[25]
It remains possible that the association between CLD and
dementia; however, there have been not enough data about that
association between 2 disease categories. Among the various
causes for CLD, the association between alcoholic liver disease
and cognitive function or risk of dementia has been most
frequently studied. One study revealed that patients with
alcoholic liver cirrhosis had a higher risk for impaired cognitive
function than in patients with liver cirrhosis from viral causes.[26]
Also, patients with end-stage liver disease requiring liver
transplantation showed signiﬁcant cognitive impairments, and
the patients with a history of alcohol abuse or dependence were
found to have worse cognitive dysfunction.[27] However,
controversy still remains about the relationship between alcohole on the all-cause mortality in patients with dementia.
Hazard ratio (95% CI)
odel 1 Model 2 Model 3
1 1 1
.07 (1.06–1.08) 1.29 (1.28–1.30) 1.21 (1.20–1.22)
.43 (1.42–1.44) 1.58 (1.57–1.58) 1.46 (1.45–1.47)
.49 (1.47–1.50) 1.84 (1.82–1.86) 1.67 (1.65–1.69)
sion, dyslipidemia, ischemic heart disease, cerebrovascular disease, heart failure, peripheral occlusive
[28]
Figure 1. Relative survival of patients after diagnosis with dementia according to the presence of type 2 diabetes and/or chronic liver disease. Kaplan-Meier curves
comparing survival in patients with dementia according to the presence of type 2 diabetes mellitus (T2D) and/or chronic liver disease (CLD) (A), and according to the
presence of T2D, nonalcoholic CLD, and/or alcoholic CLD (B).
Kim et al. Medicine (2017) 96:47 www.md-journal.comconsumption and cognitive impairment or dementia. Viral
hepatitis, one of major causes of CLD, could also be associated
with brain or cognitive function. Hepatitis C viral infection, in
particular, was more frequently related with cognitive im-
pairment.[29] In addition, although primary biliary cirrhosis is a
rare cause for CLD, cognitive impairment was prevalent in
patients with primary biliary cirrhosis independent of the severity
of liver disease.[30]
Very recently, several studies have been published which
investigated the epidemiological relationship between nonalco-
holic fatty liver disease (NAFLD) and cognitive function,[31] and
the underlying mechanisms of NAFLD on the development of
Alzheimer disease.[32] NAFLD independently associates with
lower cognitive performance, independent of cardiovascular
disease and its risk factors, in 4472 adults from general US
population[31]. Whether CLD increases the risk of dementia is
still controversial, and the pathophysiology of the relationship
between CLD and cognitive impairments remains unknown.
Among the several possible mechanisms, systemic inﬂammatory
process is one of the explanations. Inﬂammation might be one of
the major causes of dementia in patients with CLD.[33]
Furthermore, various spectrums of CLD such as viral hepatitis,
alcohol consumption, and expanded liver fat are also associated
with increased systemic inﬂammation.[34–36] Therefore, it is
plausible that chronic inﬂammation induced outside the brain
could lead to the cognitive dysfunction and development of
dementia.[32] Another underlying mechanism could be the
NAFLD-induced insulin resistance which might contribute to
the association between NAFLD and cognitive impairment or
Alzheimer disease.[37,38] In our study, the presence of CLD
increased the risk of dementia slightly compared to the control
group; however, its co-occurrence with T2D did not have any
additive effect. In the latter scenario, it is possible that the impact
of CLD was masked since the inﬂuence of T2D alone on the risk
of various types of dementia was much bigger than in patients
with CLD alone. In addition, we did not perform subgroup
analysis of the impact of the speciﬁc causes of CLD on the risk of5dementia. Therefore, it is plausible that various spectrums of
CLD might have contributed to the weakening of the effects
observed in this study.
At present, dementia is an important cause of mortality in
elderly population.[39] Many factors such as age, sex, education,
ethnicity, severity of disease, and functional impairment have
been reported as predictive of mortality in patients with
dementia.[40] Furthermore, comorbidity is common in the older
population and there have been several studies about the
relationship between various comorbidities and mortality. In a
multiethnic, population-based longitudinal study of patients with
Alzheimer disease, the presence of hypertension or T2D was
associated with increased mortality rate compared to control
groups.[41] Furthermore, dementia onset occurred earlier and the
mortality was greater in patients with T2D compared to the
patients without T2D especially in younger population; the
impact of T2D on the risk and prognosis of dementia became
attenuated in the elderly group.[11] On the contrary, there has
been no study investigating the inﬂuence of liver disease on the
mortality in patients with dementia. In our study, the presence of
only CLD markedly increased all-cause mortality compared to
the control (with neither CLD nor T2D) group (HR 1.21, 95%
CI: 1.20–1.22). Furthermore, co-occurrence of T2D and CLD,
showed additive effect on the prognosis of dementia compared to
those with T2D or CLD alone (HR 1.67, 95% CI: 1.65–1.69).
We hypothesize that enhanced systemic inﬂammation and the
liver-speciﬁc mortality in CLD population might have contribut-
ed to this additive effect; however, further studies are warranted
to corroborate this possibility.
The present study has several limitations. First, this was a
retrospective analysis, and the ﬁndings should be interpreted
accordingly. Second, the diagnosis of T2D, CLD, and dementia
was based solely on the diagnostic codes and prescription for
drugs; thus, there could have been some biases or errors. Third,
we could not categorize the speciﬁc causes of CLD, for example,
chronic viral hepatitis, alcoholic liver disease, or NAFLD. In light
of the controversy about the causal relationship between alcohol
[16] Ahtiluoto S, Polvikoski T, PeltonenM, et al. Diabetes, Alzheimer disease,
Kim et al. Medicine (2017) 96:47 Medicineconsumption and cognitive function, the use of a detailed
classiﬁcation of CLD might have provided greater insights on its
inﬂuence on the incidence or prognosis of dementia in patients
with or without T2D. Furthermore, we did not include patients
with type 1 diabetes in our study. Lastly, our analyzed solely
focused on the all-cause mortality, and not on the comprehensive
understanding of disease-speciﬁc or dementia-related mortality.
However, our study also has a number of strengths. First, as far
as we are aware, this is the ﬁrst attempt to evaluate the inﬂuence
of CLD and T2D on the incidence and prognosis of dementia.
Second, this study used a large, national sample with a relatively
long-term follow-up period; furthermore, this study accessed the
national registry data with information about mortality. Lastly,
we analyzed 2 different cohorts for evaluating the inﬂuence of
CLD and/or T2D on the incidence of dementia and the prognosis
of dementia, respectively.
In conclusion, this study found that CLDwas associated with a
modest increase in the risk of dementia; however, there was no
additive effect with T2D on the incidence of dementia. In
addition, the presence of CLD was associated with increased
mortality in patients with dementia, with or without T2D.
Further studies are warranted to evaluate the relationship
between the speciﬁc causes of CLD, that is, NAFLD and/or
alcoholic liver disease, on the risk of dementia and its prognosis.References
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